Hello and welcome to Cinclus Pharma's second quarter 2025 earnings call. As already introduced, I'm Christer Ahlberg and I'm the CEO of Cinclus Pharma. And with me today is our CFO Maria Engström and Head of Corporate and Business Development Jesper Wiklund. We will present the latest developments from the second quarter 2025 and the upcoming news flow, after which we will be happy to answer any questions you might have. Before we begin, I would like to remind our listeners that during today's call, management may make forward-looking statements that involve known and unknown risks, uncertainties, and other important factors beyond the company's control that could cause the company's actual results, performance, or achievements to differ materially from the expected results, performance, or achievements expressed or implied by such forward-looking statements. So please take a moment to review that. And with those formalities out of the way, let me begin with a high-level overview of the company, including key business updates and investment highlights, before we go into other activities in this presentation. So what do you know about Cinclus Pharma?
I mean, we are a Swedish pharmaceutical company, a late-stage development company headquartered in Stockholm and listed on Nasdaq Stockholm. We have the global rights for our lead candidate Linaprazan glurate, where we have our license and we have partners in Asia with Sinorda and a sublicense partner in China with Shanghai Pharma, and a recent partnership with Zentiva in Europe. We will address this further in the presentation.
We will discuss more about that later in the presentation.
Lina, as you know, is the next generation of PCABs with the potential to become best in class due to its unique 24-hour acid control. PCABs, as you're aware, represent the first innovation in the mechanism of action for gastric and acid-related disorders in over 25 years.
We, as a company, are focusing intensely on the high unmet medical need in patients suffering from severe erosive GERD. These patients are treated by specialists, specifically gastroenterologists. And that enables us to have a specialty commercial focus, which has many advantages in this area. It also gives us a blockbuster potential.
Our unique product provides a distinct pharmacokinetic and pharmacodynamic profile, leading to 24-hour acid control. And that gives us a very strong competitive edge and advantage compared to the old standard of care. Proton pump inhibitors, or PPIs, and the first generations of PCABs. I mean, we have a very fast onset. We have a long duration. We have a unique 24-hour acid control. Control gives us a superior healing capability, achieving results in half the time compared to other treatments. And our ambition is also to deliver superior symptom relief.
We have already delivered very good data in the Phase II study, and we are now ready to start the Phase III trial. We are expecting the last responses from the authorities in the near term. And thereafter, we are ready to initiate and start up the study.
So, everything is according to plan. We have, as we see it, and we have discussed that earlier. I mean, we have a very scientific as well as a clinically de-risked development program supported by all the proof of concept.
We have very good Phase II data demonstrating good efficacy and safety. So this is the final plan moving forward with the phase three trial, and that is the first study that we will initiate. Now is the first out of two healing studies that needs to be done before a potential approval. It's also interesting to look at the market. Perhaps the first generation market is growing globally. We see that it has been launched in 30 countries globally and is definitely gaining traction in the erosive GERD and symptomatic GERD, but also in the guidelines, which is definitely important. We see them in the guidelines in Asia.
We have also seen them included in the guidelines in the US recently.
From a sales point of view, we also see very good growth in Japan, with close to 1 billion US dollars, and in South Korea, more than 200 million USD in sales, showing significant growth there. We also see a very good start for the first PCAB on the launch in the US, and there is also interesting growth of sales in South America, with a pricing point of view at $2 or $3 per tablet, which reflects very good and healthy pricing. And before we proceed, we want to provide you with some additional information about the treatment. The key to success in this area is to control acid production.
The longer you can control the acid production and maintain a pH level above four in the stomach, the better the chances are to heal the patients. Actually, there is a linear correlation here. So if you can keep the pH above four 100%,
Over a 24-hour period, if sustained for a longer duration, you will heal the patients.
This disease is caused by acid.
And what you do is to reduce it or get rid of it, and then you will heal the patients. It's not more complicated than that.
Therefore, we think it would actually be interesting to plot the latest data from clinical studies into this linear line, as you can see. If you do that as an example, in the next slide, you can look at the latest Phase III trial from one study where they also have an acid control, PKC control of approximately 85%, and for the C and D patients over eight weeks, they delivered approximately a little bit more than 90%. And that's spot on the line here in the correlation that we have already shown in the same study. They compared themselves with lansoprazole 30mg, and they have 66% acid control. And if you look at the healing in these patients over eight weeks, it's also spot on the line in the correlation here. We know the latest PCAB in the US and Asia have less acid control than the earlier versions, with the control being below 80%. And we expect them to be around 80% of healing. It's very much perfectly fit into this line. Looking into our drug, we have 96% acid control. And if you just put it on the line there, we are then coming close to 100% healing. So this is interesting. Analysis to be done. And I just wanted to give you that information now, and the answer is yes. That's the reason why we think the biomarker with acid control is so important in this case. And that gives us an indication of what we can expect in the future.
Summary of the key events for the quarter.
Yes, we will tell you much more about the strategic alliance and license agreement with Zentiva, which gave us a deal value of €220 million in total, but also with a very good royalty of approximately 20%. Jesper will give you more information about that shortly. We have also received a waiver from both the EMA and FDA for the requirement to conduct pediatric studies of Linaprazan glurate for the treatment of Helicobacter pylori infection. Which, of course, gives us a better possibility to deliver that and make it more effective and faster. Uh, and also during the quarter, it has been clarified by the FDA that an indication with H.
Pylori provides a five-year data exclusivity extension in the US for all indications for the substance if H pylori is chosen as the first indication.
So that's a good clarification.
Absolutely. We have also published the Phase II results demonstrating high healing rates.
I mean, we are actually delivering 93% healing for severe patients in four weeks. We also deliver 100% healing of the partial responders after the PPI treatment.
This is, of course, very supportive in the continued development of the rate. Also very promising, I would say, in relation to what I just mentioned about acid control. We have also participated in the largest congress in San Diego during the quarter, where we presented new data confirming the potent acid-blocking properties of Linaprazan glurate.
And the promising results from the optimized tablet formulation that will now be used in Phase III and in the commercialization.
Commercialization later on.
We also. It's interesting to look at the market.
Now it's generating more and more interest. Within the specialist community, there is growing interest in 'Heroes of Gold,' and we have been the main sponsor of the gastroenterology conference organized by specialists in this area.
And that was in France.
And now we will also focus on reflux diseases, which is, of course, a very good sign for the future, especially as we start to focus more on this.
With that, I stop and hand over now to Jasper.